Payment overview · 2025
General Payments
$549.24
26 reported records · 11 companies
Healthcare provider profile · identity verified
Baldev K Gupta, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TRENTON, MI · NPI 1720168164
Verified facts
What the public records show
CMS Open Payments records show Baldev K Gupta, M.D. received $549.24 in general payments during 2025 across 26 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $101.81 | 18.5% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $76.91 | 14.0% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $61.30 | 11.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.08 | 11.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.09 | 10.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.70 | 9.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $40.07 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $26.02 | 4.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $24.30 | 4.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.88 | 4.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.08 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $549.24 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $101.81 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $76.91 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $61.30 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.70 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $24.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.88 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
138 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 818 | 179 |
| Eliquis | Apixaban | 586 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 548 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 119 |
| Metoprolol Tartrate | Metoprolol Tartrate | 407 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 95 |
| Lisinopril | Lisinopril | 330 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 76 |
| Furosemide | Furosemide | 277 | 82 |
| Trazodone Hcl | Trazodone Hcl | 272 | 57 |
| Omeprazole | Omeprazole | 259 | 83 |
| Losartan Potassium | Losartan Potassium | 257 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 77 |
| Gabapentin | Gabapentin | 239 | 63 |
| Alprazolam | Alprazolam | 224 | 50 |
| Metformin Hcl | Metformin Hcl | 219 | 64 |
| Sertraline Hcl | Sertraline Hcl | 204 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 66 |
| Ibuprofen | Ibuprofen | 195 | 79 |
| Simvastatin | Simvastatin | 188 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 175 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 172 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 172 | 38 |
| Prednisone | Prednisone | 163 | 69 |
| Quetiapine Fumarate | Quetiapine Fumarate | 154 | 30 |
| Levetiracetam | Levetiracetam | 145 | 24 |
| Potassium Chloride | Potassium Chloride | 145 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 138 | 34 |
| Carvedilol | Carvedilol | 134 | 34 |
| Tramadol Hcl | Tramadol Hcl | 132 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 34 |
| Allopurinol | Allopurinol | 124 | 36 |
| Clonazepam | Clonazepam | 124 | 17 |
| Donepezil Hcl | Donepezil Hcl | 124 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 120 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 120 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 45 |
| Xarelto | Rivaroxaban | 119 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 24 |
| Lorazepam | Lorazepam | 116 | 26 |
| Famotidine | Famotidine | 114 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 113 | 20 |
| Spironolactone | Spironolactone | 110 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 18 |
| Mirtazapine | Mirtazapine | 101 | 24 |
| Finasteride | Finasteride | 99 | 23 |
| Meloxicam | Meloxicam | 97 | 25 |
| Atenolol | Atenolol | 96 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 14 |
| Midodrine Hcl | Midodrine Hcl | 90 | 23 |
| Baclofen | Baclofen | 87 | 11 |
| Diazepam | Diazepam | 85 | 18 |
| Bumetanide | Bumetanide | 82 | 29 |
| Januvia | Sitagliptin Phosphate | 78 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 14 |
| Montelukast Sodium | Montelukast Sodium | 73 | 20 |
| Methocarbamol | Methocarbamol | 72 | 25 |
| Azithromycin | Azithromycin | 68 | 45 |
| Ezetimibe | Ezetimibe | 67 | 23 |
| Glipizide | Glipizide | 67 | 20 |
| Memantine Hcl | Memantine Hcl | 67 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 34 |
| Glimepiride | Glimepiride | 56 | 11 |
| Divalproex Sodium | Divalproex Sodium | 55 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | suppressed |
| Entresto | Sacubitril/Valsartan | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 50 | 12 |
| Buspirone Hcl | Buspirone Hcl | 49 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 16 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | 13 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 46 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 36 |
| Lactulose | Lactulose | 45 | 12 |
| Meclizine Hcl | Meclizine Hcl | 45 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 12 |
| Linzess | Linaclotide | 44 | suppressed |
| Risperidone | Risperidone | 44 | 14 |
| Oxcarbazepine | Oxcarbazepine | 43 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 41 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 41 | 16 |
| Latanoprost | Latanoprost | 41 | 11 |
| Novolog Flexpen | Insulin Aspart | 40 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 11 |
| Thiothixene | Thiothixene | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 13 |
| Cephalexin | Cephalexin | 37 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 36 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 34 | 17 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Austedo | Deutetrabenazine | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | 15 |
| Topiramate | Topiramate | 30 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 29 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 23 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 27 | 12 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 18 |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Nystatin | Nystatin | 22 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Budesonide | Budesonide | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 11 |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 14 |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 11 |
| Nitroglycerin | Nitroglycerin | 19 | 13 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Ursodiol | Ursodiol | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Enulose | Lactulose | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $549.24 · 26 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, AUSTEDO XR, CAPLYTA, Cologuard Collection Kit, INGREZZA, JARDIANCE, JASCAYD, JATENZO, NUPLAZID, Ozempic, Rybelsus, TRELEGY ELLIPTA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error